CFTR Modulators

PreclinicalSmall molecule

IIndiana University

CFTR Modulators is one of 42 small molecule programs targeting Cystic Fibrosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisActive, not recruiting

Cystic FibrosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

107 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Zyvox

Pfizer

Phase 2

2 3

Lamprene

Novartis

Phase 2

1 4

Mycobutin

Pfizer

Phase 2

1 5

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 6

Sirturo

WWim Janssens

Phase 2

1 7

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

18 8

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 9

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 10

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Active, not recruiting

Cystic Fibrosis

NCT04206436

Q1 2030

N/ARecruiting

Cystic Fibrosis

NCT04580368

Clinical

Trials by Indication[1]

Cystic Fibrosis4 trials

Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis

Withdrawn·UUniversidad Europea de Madrid·N/A·NCT04415268

CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis

Active, not recruiting·IIndiana University··NCT04206436·63 enrolled

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

Recruiting·—·N/A·NCT04580368·50 enrolled

Show 1 more trial

Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatment With CFTE Modulators in Children Aged 6 to 11 Years With Cystic Fibrosis With Compatible Mutation

Completed·HHospices Civils de Lyon··NCT05581056·27 enrolled

Unspecified1 trial

Response to CFTR Modulators in CF Patients Under 18 Years

Unknown status·SSociete Francaise de la Mucoviscidose··NCT04301856·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CFTR Modulators. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CFTR Modulators compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CFTR Modulators. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIndiana University

CFTR Modulators

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2030

Trials by Indication[1]

Cystic Fibrosis4 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News